ストックスクリーナーアプリを入手
1.44
4.35%
0.06
アフターアワーズ：
1.44
前日終値:
$1.38
開ける：
$1.42
24時間の取引高:
225.01K
Relative Volume:
2.30
時価総額：
$48.43M
収益：
-
当期純損益:
$-28.32M
株価収益率:
-0.1358
EPS:
-10.6039
ネットキャッシュフロー:
$-15.52M
1週間 パフォーマンス:
-10.56%
1か月 パフォーマンス:
-4.00%
6か月 パフォーマンス:
-59.55%
1年 パフォーマンス:
-68.70%
1日の値動き範囲:
$1.28
$1.45
1週間の範囲:
$1.28
$1.64
52週間の値動き範囲:
$1.28
$9.50
Dogwood Therapeutics Inc Stock (DWTX) Company Profile
名前
Dogwood Therapeutics Inc
セクター
電話
(866) 620-8655
住所
44 MILTON AVENUE, ALPHARETTA
Compare DWTX vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DWTX
Dogwood Therapeutics Inc
|
1.44 | 46.41M | 0 | -28.32M | -15.52M | -10.60 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Dogwood Therapeutics Inc (DWTX) 最新ニュース
Price to sales forward of Dogwood Therapeutics, Inc. – NASDAQ:DWTX - TradingView
DWTXDogwood Therapeutics Inc Latest SEC Filings - Finviz
Dogwood Therapeutics Names OrbiMed’s Iain Dukes Chair of Scientific Advisory Board - citybiz
Dogwood Therapeutics appoints Iain Dukes to lead advisory board - Investing.com
Dogwood Therapeutics appoints Iain Dukes to lead advisory board By Investing.com - Investing.com Canada
Press Release: Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board - Moomoo
Dogwood Therapeutics, Inc.(NasdaqCM:DWTX) added to Russell Microcap Value Benchmark Index - marketscreener.com
Dogwood Therapeutics, Inc.(NasdaqCM: DWTX) added to Russell Microcap Index - marketscreener.com
Dogwood Therapeutics, Inc.(NasdaqCM: DWTX) added to Russell 3000E Index - marketscreener.com
Dogwood Therapeutics, Inc.(NasdaqCM: DWTX) added to Russell 3000E Value Benchmark - marketscreener.com
DWTX Forecast — Price Target — Prediction for 2027 - TradingView
Dogwood Therapeutics Inc Actuals & Estimates (NASDAQ:DWTX) - TradingView
Dogwood Therapeutics Inc (DWTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Number of shareholders of Dogwood Therapeutics, Inc. – NASDAQ:DWTX - TradingView
Dogwood Therapeutics Shareholders Approve Key Governance Measures - The Globe and Mail
Dogwood Therapeutics Inc (DWTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Dogwood Therapeutics shareholders approve board proposals at annual meeting By Investing.com - Investing.com South Africa
Dogwood Therapeutics, Inc. Announces Amendments to Articles of Incorporation and Key Shareholder Voting Results – June 2026 – Minichart - Minichart
Dogwood Therapeutics Inc (DWTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Dogwood Therapeutics Inc (DWTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Dogwood Therapeutics shareholders approve board proposals at annual meeting - Investing.com UK
Dogwood Therapeutics (DWTX) investors approve share increase and annual Say-on-Pay - Stock Titan
[Form 4] Dogwood Therapeutics, Inc. Insider Trading Activity - Stock Titan
Dogwood Therapeutics (DWTX) director awarded 16,800 options at $1.50 strike price - Stock Titan
Dogwood Therapeutics Inc (DWTX) Institutional Confidence - TradingKey
Dogwood Therapeutics Inc (DWTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Dogwood Therapeutics Inc (DWTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Dogwood Therapeutics Inc (DWTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Dogwood Therapeutics Inc (DWTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Dogwood Therapeutics Inc. (DWTX) Q1 2026 Earnings: Narrower-than-Expected Loss Lifts SharesAnnual Financial Report - newsline.com
Dogwood Therapeutics Inc. (DWTX) Q1 2026 Earnings: Narrower-than-Expected Loss Signals Cost Discipline - newsline.com
DWTX Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift SharesFinal Results - newsline.com
DWTX Q1 2026 Earnings: Narrower-than-expected loss as stock slides 8.5%EBITDA Analysis - newsline.com
DWTX Q1 2026 Earnings: Narrower Loss Meets Investor Skepticism as Stock DeclinesUpward Estimate Revision - newsline.com
DWTX News | DOGWOOD THERAPEUTICS INC (NASDAQ:DWTX) - ChartMill
Dogwood Therapeutics Inc. (DWTX) Q1 2026 Earnings: Better-Than-Expected Loss Highlights Cost Discipline - newsline.com
Dogwood Therapeutics Inc. (DWTX) Rises 1.2% as Stock Holds Above Key SupportVolume Climax - newsline.com
Dogwood Therapeutics Inches Lower as Stock Tests Key Support Near $1.69Take Profit Levels - Newser
Dogwood Therapeutics Inc. (DWTX) Q1 2026 Earnings: Narrower Loss Surprises as Pre‑Revenue Biotech Focuses on Pipeline ProgressEarnings Whisper Number - newsline.com
Dogwood Therapeutics Q1 2026 Earnings: Narrower-Than-Expected Loss Amid Continued Preclinical DevelopmentEPS Growth Rate - Newser
Analysts Are Bullish on Top Healthcare Stocks: Invivyd (IVVD), Century Therapeutics (IPSC) - The Globe and Mail
PRODU - produ
DWTX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $12.00 - GuruFocus
H.C. Wainwright Maintains Dogwood Therapeutics(DWTX.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Dogwood launches 12-week extension study for pain drug Halneuron - Investing.com UK
Dogwood launches 12-week extension study for pain drug Halneuron By Investing.com - Investing.com Australia
Dogwood Therapeutics Announces Commencement of Halneuron® - GlobeNewswire
Dogwood Therapeutics, Inc. Q1 2026 SEC 10-Q Filing – Financial Statements, Management Discussion, and Risk Factors – Minichart - minichart.com.sg
Dogwood Therapeutics 1Q Rev $0.00 >DWTX - Moomoo
Armistice Capital (NASDAQ: DWTX) reports 9.99% Dogwood stake - Stock Titan
Dogwood Therapeutics 1Q 2026: Revenue $2.41M, EPS ($0.15) — 10-Q Summary - TradingView
Dogwood Therapeutics Inc (DWTX) 財務データ
収益
当期純利益
現金流量
EPS
1.17%
2.48%
大文字化:
|
ボリューム (24 時間):